Alumis (NASDAQ:ALMS) Receives Buy Rating from HC Wainwright

by · The Markets Daily

Alumis (NASDAQ:ALMS – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $26.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 222.98% from the company’s current price.

Other research analysts have also issued research reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Robert W. Baird started coverage on Alumis in a research report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price on the stock. Finally, Baird R W upgraded Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Alumis presently has an average rating of “Buy” and a consensus target price of $26.83.

View Our Latest Stock Analysis on Alumis

Alumis Trading Down 8.4 %

Shares of Alumis stock opened at $8.05 on Monday. Alumis has a 52 week low of $7.46 and a 52 week high of $13.53. The company has a fifty day simple moving average of $9.41.

Institutional Trading of Alumis

A number of large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. purchased a new position in Alumis in the third quarter valued at $191,000. Barclays PLC purchased a new position in shares of Alumis in the 3rd quarter valued at about $197,000. Geode Capital Management LLC purchased a new stake in shares of Alumis during the third quarter worth approximately $3,266,000. State Street Corp acquired a new stake in Alumis in the third quarter valued at approximately $866,000. Finally, Stifel Financial Corp purchased a new position in Alumis in the third quarter worth approximately $931,000.

Alumis Company Profile

(Get Free Report)

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

See Also